Regulatory Affairs in the Pharmaceutical Industry

In the pharmaceutical industry, regulatory affairs (RA) is the function that owns a company’s relationship with drug and biologic regulators across the entire life of a product — from the first pre-IND meeting through the marketing application, the approval decision, and every change made to the product after it reaches the market. It sits organizationally inside the sponsor company, not the government: RA staff draft and file the submissions, run the strategy for what to ask a regulator and when, and carry ongoing accountability for keeping the product’s regulatory record current for as long as it stays on the market.

This is a distinct function from regulatory affairs inside a research institution, which handles investigator-held INDs/IDEs for academic studies rather than a company’s commercial product pipeline, and from regulatory intelligence, the input layer that monitors the external regulatory environment and feeds RA’s strategy rather than filing anything itself. This page covers what the pharma RA function actually does across the product lifecycle, its core day-to-day responsibilities, how the work changes before versus after approval, how it differs from adjacent functions, and the career path into and through it.

What Regulatory Affairs Owns Across the Product Lifecycle

RA’s scope is best understood by lifecycle stage, because the function’s priorities and the regulatory tools it uses change substantially from development through post-market.

Development-Stage Strategy and Agency Meetings

Before a marketing application is anywhere close to ready, RA is already setting strategy: interpreting applicable guidance, deciding which regulatory pathway fits the product (standard approval, Priority Review, accelerated approval, breakthrough designation), and managing the formal meeting process with FDA’s drug and biologic review divisions (CDER/CBER). FDA groups these meetings into defined categories under its PDUFA meeting-management framework: Type A meetings resolve an otherwise-stalled program (clinical holds, dispute resolution) and are targeted within 30 calendar days of request; Type B meetings occur at defined development milestones — pre-IND, End-of-Phase 2, pre-NDA/BLA — generally once per phase, targeted within 60 days; Type C covers any other topic outside those milestones, targeted within 75 days; and two categories added under PDUFA VII, Type D (a narrow 1–2 topic meeting needing input from a limited number of FDA disciplines) and INTERACT (early-stage advice for novel products facing issues with no existing guidance), round out the framework. RA typically owns the meeting request, the briefing book, and the agency correspondence that follows.

Building and Submitting the Marketing Application

When clinical development is far enough along, RA assembles the marketing application: a New Drug Application (NDA) for a drug product under the FD&C Act, or a Biologics License Application (BLA) for a biological product, defined at 21 CFR 601.2 as a request for permission to introduce a biologic into interstate commerce. Both are built to the ICH Common Technical Document (CTD) structure — a harmonized five-module dossier (administrative, CTD summaries, quality, nonclinical, clinical) used across NDA, BLA, and EU MAA submissions — and filed electronically per the eCTD specification. RA does not generate the underlying nonclinical or clinical data; it compiles, formats, and files it, and owns the narrative that ties the dossier together into a coherent regulatory argument.

The Approval Decision

After submission, FDA generally has 60 days to make a filing decision, then runs its substantive review. The outcome is either approval, or a Complete Response Letter (CRL) — issued only after a completed review cycle under 21 CFR 314.110, with grounds for non-approval specified at 21 CFR 314.125 (NDA) and 314.127 (ANDA). A CRL is distinct from a refuse-to-file letter, which happens pre-review over an incomplete application, and from an approval that carries post-marketing requirements, where the product is approved but FDA has attached conditions. RA owns the response strategy to a CRL — deciding what data or argument closes each deficiency and running the resubmission.

Post-Approval: Labeling, Change Control, and Lifecycle Maintenance

Approval does not end RA’s involvement — it shifts the work from getting the product approved to keeping the approved product’s regulatory record accurate as the product itself, its manufacturing, and its safety profile evolve. Every post-approval change to an NDA falls into one of three reporting tiers under 21 CFR 314.70 (a parallel structure applies to BLAs under 601.12): a Prior Approval Supplement (PAS) for changes with substantial potential to affect identity, strength, quality, purity, or potency — most formulation and manufacturing-process changes, and most labeling changes — which require FDA approval before the changed product can be distributed; a Changes Being Effected (CBE) supplement for moderate-risk changes, where a standard CBE-30 allows distribution 30 days after FDA receives it unless FDA objects, and a narrower CBE-0 covers specific categories such as safety labeling enhancements and permits distribution immediately upon receipt; and an Annual Report change for minimal-risk items such as certain editorial labeling edits or identical-equipment swaps, which need no pre-distribution approval at all. RA classifies every proposed change into the correct tier, prepares the supplement, and tracks the product’s full labeling history. On the safety side, RA also owns or co-owns the periodic aggregate safety reporting cadence — the Periodic Benefit-Risk Evaluation Report (PBRER) defined in ICH E2C(R2) for the post-approval period, distinct from the pre-approval Development Safety Update Report (DSUR) under ICH E2F.

Core Day-to-Day Responsibilities

• Regulatory strategy. Choosing and sequencing the pathway to approval, including which designations to pursue and when to request a formal agency meeting.
• Submissions management. Compiling, formatting, and filing INDs, marketing applications, and every post-approval supplement, in the correct CTD/eCTD structure.
• Agency liaison. Owning the working relationship with reviewers — meeting requests, briefing documents, information requests, and CRL responses.
• Labeling. Drafting and negotiating prescribing information and patient labeling, and managing every subsequent labeling change through its correct reporting tier.
• Change control. Classifying manufacturing, formulation, and process changes into PAS/CBE/Annual Report tiers and filing the resulting supplement.
• International submissions. Adapting the core CTD dossier for other regulatory regions (EMA, and other ICH and non-ICH authorities), where format is harmonized but requirements and timelines are not identical.
• Cross-functional review. Reviewing promotional material, clinical protocols, and manufacturing change proposals for regulatory risk before they go external or get implemented.

How the Role Differs Before vs. After Approval

Pre-approval, RA work is strategy-heavy and episodic: a small number of high-stakes agency meetings and one large marketing-application submission, built around getting a novel product across a single approval decision. Post-approval, the work becomes higher-volume and continuous: a steady stream of manufacturing, labeling, and safety-driven supplements, each individually smaller than the original application but collectively constant, plus periodic safety reporting and monitoring for competitor and guidance changes that could affect the product’s labeling or claims. Professionals sometimes specialize in one side or the other — a development/submissions-focused RA role versus a labeling and lifecycle-management role — though many mid-career RA professionals move between both.

Regulatory Affairs vs. Adjacent Functions

The name “regulatory affairs” gets applied to several distinct roles, and mixing them up leads to miscalibrated expectations, especially for someone new to the field or moving in from adjacent research administration.

• Regulatory affairs (pharma industry, this page) — the sponsor-side execution function: determines pathway, files submissions, owns agency correspondence, manages labeling and post-approval change, for a company’s own product pipeline.
• Regulatory intelligence — the input layer that monitors the external regulatory environment (new guidance, competitor approvals, policy shifts) and turns it into a documented input to RA’s strategy. It does not file anything itself.
• Medical Science Liaison (MSL) — a field-based scientific role that engages external Key Opinion Leaders on clinical and mechanistic data. Structurally separated from RA and from commercial functions; MSLs do not draft submissions or own agency correspondence.
• Institutional/academic regulatory affairs — the research-administration function inside a university or academic medical center that files investigator-held INDs/IDEs for individual studies. Same name, materially different scope, employer, and submission volume than the pharma-industry function this page describes.

Career Path, Skills, and Credentials

Entry into pharma RA comes from several directions: a life-sciences or pharmacy degree (a PharmD or an advanced life-sciences degree is common but not universal) moving directly into an RA associate role; a lateral move from clinical operations, quality, or medical writing, where familiarity with clinical data and documentation transfers directly; or, less commonly, a regulatory-agency background moving to the industry side. The typical ladder runs from Regulatory Affairs Associate/Specialist, through Senior Specialist and Manager (usually where product- or therapeutic-area ownership begins), to Associate Director/Director (strategy across a portfolio) and VP-level roles (regulatory policy and organizational strategy). The Regulatory Affairs Certification (RAC), administered by the Regulatory Affairs Professionals Society (RAPS), is the field’s primary standalone credential — offered in separate Drugs and Devices designations — and is knowledge-based rather than a practice license, since no formal license exists for this profession. It is commonly confused with clinical-conduct credentials aimed at a different job; see RAC vs. CCRP Certification for how the two actually differ.

Frequently Asked Questions

What does a regulatory affairs professional do in the pharmaceutical industry?

They own a drug or biologic product’s relationship with regulators across its lifecycle: setting regulatory strategy, filing the IND and marketing application, managing FDA meetings and correspondence, drafting and maintaining labeling, and classifying and filing every post-approval change.

How is pharma regulatory affairs different from regulatory intelligence?

Regulatory intelligence monitors the external environment and feeds information into strategy; regulatory affairs is the execution function that actually files submissions and owns the agency relationship. See Regulatory Intelligence: Building a Monitoring Function for the fuller distinction.

Do you need a PharmD or advanced degree to work in pharma regulatory affairs?

It is common but not universal. Many RA professionals enter with a life-sciences background or move laterally from clinical operations, quality, or medical writing; an advanced degree helps most at the strategy/director level rather than as a strict entry requirement.

What is a Prior Approval Supplement?

A PAS is the reporting category under 21 CFR 314.70 for post-approval changes with substantial potential to affect a drug’s identity, strength, quality, purity, or potency — most formulation and manufacturing-process changes fall here, and the change cannot be distributed until FDA approves the supplement.

Is pharma regulatory affairs the same as regulatory affairs at a university or research institution?

No. They share a name but not a scope: the institutional version files investigator-held INDs/IDEs for individual academic studies, while the pharma-industry function on this page manages a company’s own commercial product pipeline end to end.